Nippon Boehringer Ingelheim Initiates Phase II Trial For Hepatitis C Drug
This article was originally published in PharmAsia News
Executive Summary
Nippon Boehringer Ingelheim starts Phase II trials in Japan for BI201335, an antiviral agent for patients with chronic hepatitis C
|
Nippon Boehringer Ingelheim starts Phase II trials in Japan for BI201335, an antiviral agent for patients with chronic hepatitis C. BI 201335 works to prevent the virus from replicating by binding to the HCV protease. The company has focused on antiviral HCV drug development; and BI201335 is Nippon BI's first Hepatitis C drug developed in Japan. Similar trials are also being conducted outside Japan. (Click here for more - Japanese language) "Nippon BI Starts Domestic Phase II Trial For Hepatitis C Drug" - Chemical Daily (2/3/2010) |